Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating critical details on collagen efficacy studies, FDA clearances, and insider share movements across Sanara MedTech’s dense SEC filings can feel like performing surgery without proper lighting. The company’s focus on advanced wound care means its 10-K annual report is packed with clinical trial data, R&D expenses, and licensing disclosures that easily surpass 200 pages.
Stock Titan’s AI-powered platform removes that complexity. Our system parses every Sanara MedTech quarterly earnings report 10-Q filing, highlights shifts in gross margin from surgical wound products, and delivers plain-English explanations of each risk factor. Form 4 alerts surface Sanara MedTech insider trading Form 4 transactions the moment they hit EDGAR, so you can spot executive stock activity in real time. Need to decode an 8-K about a newly cleared collagen dressing? The "Sanara MedTech 8-K material events explained" module summarizes the impact on revenue guidance within seconds.
Whether you’re comparing segment performance, checking Sanara MedTech proxy statement executive compensation, or simply searching for "Sanara MedTech SEC filings explained simply," our coverage spans every document type: 10-K, 10-Q, 8-K, DEF 14A, S-1, and more. AI-generated keyword tagging lets you jump straight to reimbursement discussions, while expert commentary outlines how collagen science drives top-line growth. Stop wading through PDFs—access Sanara MedTech annual report 10-K simplified, monitor Sanara MedTech Form 4 insider transactions real-time, and understand each filing’s relevance to wound-care innovation in one streamlined hub.
Sanara MedTech Inc. (SMTI) Form 3 shows Ashley M. Mackey reported beneficial ownership of 2,412 shares of the issuer's common stock. The report cites an event date of 08/29/2025 and the form is signed on 09/04/2025. The filing identifies the reporting person as a Director and indicates Controller in the relationship field. No derivative securities or additional holdings are reported.
Sanara MedTech Inc. director and Chief Accounting & Chief Administrative Officer Michael D. McNeil reported a Form 4 showing an 08/19/2025 transaction in which 2,324 shares of common stock were withheld to satisfy tax withholding for the accelerated vesting of 9,543 restricted shares previously granted. The filing states no shares were issued or sold; the per-share withholding value was $30.86, reflecting the Nasdaq market price on the vesting date. After the withholding, Mr. McNeil beneficially owns 28,587 common shares.
Sanara MedTech Inc. reported quarterly net revenue of $25.83 million and six‑month net revenue of $49.26 million, increases versus the prior year driven by higher sales of soft tissue repair and bone fusion products. Gross profit rose to $23.89 million for the quarter, reflecting strong product margins despite modest cost of goods sold.
The company recorded a net loss attributable to shareholders of $2.01 million for the quarter (net loss per share $0.23), improved from a loss of $3.50 million the prior year quarter; year‑to‑date net loss was $5.54 million (vs. $5.27 million prior year). Cash increased to $16.96 million and total assets grew to $98.77 million. Leverage rose materially: long‑term debt, net of issuance costs, was $44.22 million (up from $30.69 million) following additional borrowings under the CRG Term Loan. The company completed the CarePICS acquisition on April 1, 2025 (total purchase consideration $3.48 million) and recorded higher investments and earnout liabilities. The period shows revenue growth and improved quarterly profitability but higher interest and contingent obligations from financing and acquisitions.
Sanara MedTech Inc. announced its financial results for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1 to this Current Report. The report explicitly states the press release is furnished rather than filed, and therefore the exhibit is not subject to Section 18 liability nor automatically incorporated by reference into other securities filings unless expressly stated.
The body of the Current Report contains no financial figures or performance metrics, so readers must consult Exhibit 99.1 for the company’s detailed results and any quantitative disclosures.
Sanara MedTech (ticker SMTI) is listed on the Nasdaq Capital Market and identifies its principal executive offices in Fort Worth, Texas.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
